VPIM
PRLD icon

Vanguard Personalized Indexing Management’s Prelude Therapeutics PRLD Stock Holding History

Vanguard Personalized Indexing Management’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-11,925
Closed -$15.2K – 1895
2024
Q4 		$15.2K Buy
+11,925
New +$15.8K ﹤0.01% 1784

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Personalized Indexing Management's PRLD Position: Q1 2025 in Review

Vanguard Personalized Indexing Management sold out of Prelude Therapeutics (PRLD) in Q1 2025, closing a stake of 11,925 shares — an estimated $15.2K sold.

Vanguard Personalized Indexing Management first reported a position in PRLD in Q4 2024 and held it in 1 quarter. The position peaked at $15.2K in Q4 2024. 59 funds tracked by Wall St. Rank hold PRLD as of Q1 2025.

  • Vanguard Personalized Indexing Management reported no remaining Prelude Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Vanguard Personalized Indexing Management sold 11,925 Prelude Therapeutics shares in Q1 2025, an estimated $15.2K.
  • Vanguard Personalized Indexing Management first reported a position in Prelude Therapeutics in Q4 2024 and held it in 1 quarter.
  • Vanguard Personalized Indexing Management's Prelude Therapeutics position peaked at $15.2K in Q4 2024.
  • 59 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q1 2025.

Based on Vanguard Personalized Indexing Management's 13F filing for Q1 2025, filed 14 May 2025.